Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis

Abstract

Background: The receptor tyrosine kinase mesenchymal-epithelial transition factor (MET) is frequently altered in cancers and is a common therapeutic target for cancers with MET variants. However, abnormal MET alterations and their associations with patient outcome across different cancer types have not been studied simultaneously. In this study, we try to fill the vacancy in a comprehensive manner and capture the full MET alteration spectrum. Methods: A total of 10,967 tumor samples comprising 32 cancer types from The Cancer Genome Atlas (TCGA) datasets were analyzed for MET abnormal expression, mutations, and copy number variants (CNVs). Results: MET abnormal expression, alteration frequency, mutation site distribution, and functional impact varied across different cancer types. Lung adenocarcinoma (LUAD) has most targetable mutations located in the juxtamembrane domain, and both high expression and amplification of MET are significantly associated with poor prognosis. Kidney renal papillary cell carcinoma (KIRP) harbored the third highest alteration frequency of MET, which was dominated by mutations. While most mutations were in the Pkinase_Tyr domain, a few were targetable. Pancreatic adenocarcinoma (PAAD) harbors very few alterations, but increased MET expression is associated with poor outcomes. Esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), and ovarian serous cystadenocarcinoma (OV) had similar characteristics: a high frequency of MET CNVs but relatively few MET mutations, and high MET expression associated with poor prognosis. Conclusion: This study provided significant and comprehensive information regarding MET abnormal expression, alterations (mutations and CNVs), and their clinical associations among 32 cancer types and offered insights into the full MET alteration spectrum and its implications for prognosis and treatment.

Expression profile and prognostic values of Chromobox family members in human glioblastoma

“…The Chinese Glioma Genome Atlas (CGGA) database containing over 600 glioma samples was chosen. cBioPortal cBioPortal is a comprehensive publicly web tool that could provide researchers with visual and multidimensional tumor genomics data [52,53]. In our study, the Glioblastoma Multiforme (TCGA, Firehose Legacy) dataset containing 604 samples was selected to analyze the CBXs in cBioPortal.…”

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications

“…In addition to mutations, CNVs can also affect the expression and activation of cancer-associated genes, involving in the occurrence and development of many tumors 27 , 28 . MEK1 CNV frequency varied greatly in different tumors.…”

Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma

“…cBioPortal is a public web application designed for better utilization of genomics and clinical data in cancer researches [ 43 , 44 ]. We use cBioPortal to retrieve a dataset containing 360 patients with HCC (TCGA, Firehose Legacy), then the co-expression and gene alteration analysis of GSDM family members were performed through cBioPortal.…”